Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTango reports 92% response rate in pancreatic cancer trial, plans Phase 3 study
Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
high
Phase 1/2 trial of vopimetostat plus daraxonrasib achieved 92% response rate in 12 pancreatic cancer patients, with 90% progression-free at six months and 100% disease control—exceptionally strong results for heavily pre-treated metastatic disease.
Item 7.01: Press Release verify on EDGAR → -
high
Company plans to advance vopimetostat plus daraxonrasib into Phase 3 randomized controlled trial for first-line pancreatic cancer and explore registration pathways for second-line treatment, pending regulatory feedback.
Item 7.01: Press Release verify on EDGAR → -
high
Combination therapy showed manageable safety profile with mostly mild-to-moderate side effects, no treatment discontinuations, and no severe (grade 4 or 5) treatment-related adverse events across dose levels.
Item 7.01: Press Release verify on EDGAR → -
medium
Alternative combination using zoldonrasib showed 52% response rate in 27 pancreatic cancer patients with 74% progression-free at six months, demonstrating meaningful activity though lower than daraxonrasib combination.
Item 7.01: Press Release verify on EDGAR → -
medium
Small lung cancer cohort (3 patients) achieved 100% response rate with vopimetostat plus daraxonrasib, suggesting potential activity in NSCLC that may warrant further investigation.
Item 7.01: Press Release verify on EDGAR →
Summary
Tango Therapeutics disclosed breakthrough Phase 1/2 clinical trial results for its lead drug candidate vopimetostat combined with Revolution Medicines' RAS(ON) inhibitor daraxonrasib. In pancreatic cancer patients—one of the most difficult-to-treat cancers—the combination achieved a 92% objective response rate with all patients achieving disease control.
These results are particularly impressive given that patients were heavily pre-treated with prior therapies. The safety profile was manageable with no patients stopping treatment due to side effects. For retail investors, this represents a major inflection point for Tango's pipeline. Pancreatic cancer has few effective treatment options, and these response rates significantly exceed typical benchmarks.
The company's decision to advance directly into Phase 3 development signals confidence in the data and accelerates the path toward potential FDA approval and commercialization. The combination also showed activity in lung cancer, suggesting broader market potential. Watch for the Phase 3 trial initiation timeline and FDA feedback on the registration strategy. The company will need to confirm these results in a larger, randomized study, but the strength of early data positions vopimetostat as a potentially transformative asset for both patients and shareholders.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Tango disclosed Phase 1/2 trial data for vopimetostat combined with RAS(ON) inhibitors, showing initial safety and efficacy results.
Added in current filing · verify on EDGAR →
On June 8, 2026, Tango Therapeutics, Inc. (the “Company” or “Tango”) issued a press release announcing the initial safety and efficacy data from the Company’s Phase 1/2 combination trial evaluating vopimetostat in combination with RAS(ON) inhibitors from Revolution Medicines, Inc.
The company publicly disclosed initial safety and efficacy data from an ongoing Phase 1/2 clinical trial testing vopimetostat (Tango's drug candidate) in combination with RAS(ON) inhibitors from Revolution Medicines. This represents a material clinical development milestone for investors tracking the company's pipeline progress and potential partnership value.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Based on these data, the Company intends to advance this combination approach into Phase 3 development for patients with MTAP-deleted pancreatic cancer. Subject to feedback from regulatory authorities, the Company plans to initiate a Phase 3 randomized-controlled trial in front-line pancreatic cancer and evaluate opportunities to advance the second line combination towards registration phase.
The company is advancing the vopimetostat plus daraxonrasib combination into Phase 3 trials for pancreatic cancer based on the strong Phase 1/2 results. They plan to conduct a randomized controlled trial in first-line pancreatic cancer and explore registration pathways for second-line treatment, representing a significant advancement in the drug development program.
Event · Item 9.01 — Financial Statements and Exhibits
Tango Therapeutics filed an 8-K attaching a press release and presentation dated June 8, 2026, with no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
99.1 Press Release of Tango Therapeutics, Inc., dated June 8, 2026 99.2 Presentation of Tango Therapeutics, Inc.
The company attached a press release and presentation dated June 8, 2026, as exhibits to this 8-K. The filing body provides no details about the content or purpose of these materials, making it impossible to assess materiality without reviewing the actual exhibits.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify